Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGB 21447

Next Previous
X
Search
Drug Profile

BGB 21447

Alternative Names: BGB-21447

Latest Information Update: 07 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Class Antineoplastics
  • Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Jan 2025 BeiGene plans a phaseI trial for HER2 negative breast cancer (Metastatic disease, HER2-negative-breast-cancer, Late-stage diseases, Combination therapy) (PO) in January 2025 (NCT06756932)
  • 20 Jun 2023 Phase-I clinical trials in Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater) in China (PO) (NCT05828589)
  • 20 Jun 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in China (PO) (NCT05828589)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top